Ivermectin occupies an unusual place in modern medicine: it is a genuinely important drug, approved and manufactured for both humans and animals, yet the two supply chains are governed by different regulatory pathways, different quality thresholds, and different formulations entirely. This article explains, plainly and without hype, what Good Manufacturing Practice (GMP) actually requires for human pharmaceuticals, how the veterinary manufacturing framework differs, and why that distinction matters if a patient and physician are discussing ivermectin's approved and investigational uses.
A Molecule From the Soil: Origins and Approved Uses
Ivermectin descends from avermectin, a compound isolated from Streptomyces avermitilis, a bacterium found in soil near a golf course in Japan and identified by microbiologist Satoshi Ōmura. Working with parasitologist William C. Campbell at Merck, researchers developed it into a medicine that has since prevented untold suffering from parasitic disease. Ōmura and Campbell shared the 2015 Nobel Prize in Physiology or Medicine for the discovery. There is something worth pausing on here: a compound quietly present in ordinary soil, waiting to be found, has done more to relieve human misery than most synthesized inventions of the twentieth century. It is a small but real reminder that the created world is not empty of provision.
In humans, the FDA has approved oral ivermectin for intestinal strongyloidiasis and onchocerciasis (river blindness), and topical formulations for head lice and for rosacea. Since 1987, Merck has donated ivermectin for onchocerciasis control through the Mectizan Donation Program, one of the longest-running drug donation efforts in public health history. These are the only conditions for which ivermectin carries FDA approval in humans. Any other human use, including as a treatment for viral illness, is off-label, meaning a physician may in some circumstances prescribe it using clinical judgment, but the FDA has not reviewed it as safe and effective for that purpose.
In animals, ivermectin is approved across multiple species — dogs, cats, horses, cattle, sheep and swine — chiefly for heartworm prevention and control of internal and external parasites. These are legitimate, well-established veterinary uses, not a lesser or careless category of medicine. They are simply built for a different patient.
One Drug, Two Regulatory Pathways
Within the FDA, human drugs are reviewed by the Center for Drug Evaluation and Research (CDER) through a New Drug Application (NDA), while animal drugs are reviewed by the Center for Veterinary Medicine (CVM) through a New Animal Drug Application (NADA). Both pathways require evidence of safety and efficacy, but the evidence is generated in, and calibrated for, different species. A veterinary approval demonstrates that a formulation is safe and effective in the target animal — a horse, a dog, a steer — at a specific weight-based dose. It says nothing about human safety at that dose, because that question was never asked or tested in the veterinary approval process.
Manufacturing facilities for both human and animal drugs are subject to FDA's current Good Manufacturing Practice regulations under Title 21 of the Code of Federal Regulations, Part 211, which governs the production of finished pharmaceuticals generally. In that narrow sense, "GMP" is not a lower bar for veterinary drugs; a licensed veterinary manufacturing plant is still inspected, still required to validate its processes, and still expected to produce a consistent, uncontaminated product. The meaningful difference is not that one set of factories is sloppy and the other pristine — it is that the two systems are built around entirely different clinical targets, tolerances, and quality specifications.
What GMP Actually Requires — and Where the Paths Diverge
Human pharmaceutical GMP is built around the assumption that the tablet or capsule will be swallowed by a person whose body weight may range from under 50 pounds to over 300, whose kidney and liver function vary, and whose dose must be exact to the milligram. That drives requirements most people never see: validated assays confirming potency within a tight percentage of label claim, dissolution testing to confirm the drug releases predictably in the gut, stringent limits on impurities measured in parts per million, and content uniformity testing across every batch to ensure one tablet does not carry meaningfully more or less active drug than the next.
Veterinary manufacturing meets its own rigorous specifications, but they are set against a different reference point. Impurity and excipient tolerances are established for the target species' physiology, not a human's. A paste, gel, or pour-on formulated for a 1,200-pound horse or a 1,000-pound steer is not designed with the dosing precision a 150-pound human requires; it is designed to be measured against an animal's body weight using a calibrated syringe plunger, often in units that do not translate cleanly to a human dose at all. Flavoring agents, carriers, and combination ingredients (such as added dewormers for other parasite species) are chosen for palatability and safety in livestock or companion animals — not evaluated for human ingestion.
Why a Horse Dewormer Is Not a Human Medicine
This is where the distinction stops being a regulatory technicality and becomes a genuine safety concern. During 2021, as public interest in ivermectin for COVID-19 grew, poison control centers in several states reported a marked rise in calls related to ivermectin exposure. The Mississippi State Department of Health stated that a substantial share of the calls it fielded that year involved people who had taken formulations intended for livestock, not the human oral tablet. The concentrations in animal products, and the absence of human-calibrated dosing guidance, made accurate self-dosing very difficult, and several patients experienced symptoms consistent with overdose, including gastrointestinal distress, low blood pressure, and neurological effects such as confusion or seizures in severe cases.
This is not a judgment on veterinary medicine, which serves animals well within its own approved use. It is a statement about mismatch: taking an animal-formulated product at animal-calculated concentrations, without the impurity limits, dosing precision, or clinical oversight built into the human pharmaceutical system, is a materially different act from taking a human-approved tablet under a physician's guidance.
Ivermectin and COVID-19: Separating the Laboratory From the Clinic
Interest in ivermectin for COVID-19 began with a laboratory finding: in 2020, researchers at Monash University in Australia, publishing in the journal Antiviral Research, reported that ivermectin reduced SARS-CoV-2 viral RNA in monkey kidney cells (Vero cells) in a laboratory dish. That is a legitimate in vitro finding, but it required a drug concentration far higher than can be achieved safely in the human bloodstream at approved doses — a gap that subsequent pharmacokinetic analyses highlighted clearly. A cell-culture result does not establish that a drug works, or is safe, in a living person.
Since then, larger and better-controlled human trials have addressed the question directly. The TOGETHER trial, a randomized platform trial coordinated with McMaster University and conducted in Brazil, published in the New England Journal of Medicine in 2022, found no significant reduction in COVID-19 hospitalization among patients treated with ivermectin compared with placebo. The NIH-funded ACTIV-6 trial, a large randomized study across US sites published in JAMA, similarly found no meaningful benefit in symptom resolution at standard or higher approved doses. A Cochrane systematic review of the accumulated trial evidence concluded that the existing data did not support ivermectin's use for COVID-19 treatment or prevention outside of formal clinical trials, while noting that trial quality across the field was uneven. Readers should understand this as a genuinely settled point in the peer-reviewed randomized-trial literature, even as it remains a subject of public debate.
Stewardship, Informed Consent, and Working With Your Own Doctor
None of this diminishes ivermectin's real value. For onchocerciasis, strongyloidiasis, and topical parasitic conditions, it is a safe and effective medicine when manufactured to human pharmaceutical standards and taken at the approved dose under medical supervision. Caring for one's own health, and one's family's health, means taking that seriously in both directions: neither dismissing a genuinely useful drug out of fashion, nor reaching for an animal product because it is easier to obtain. A physician can access accurate information about a patient's kidney and liver function, other medications, and the actual evidence base for any proposed use, on- or off-label. That conversation, grounded in informed consent and mutual respect between patient and doctor, is the responsible way to weigh any treatment decision — including one involving a drug as genuinely remarkable, in its proper place, as ivermectin.
Key takeaway: Ivermectin is a valuable, well-studied medicine for its approved human uses, but human and veterinary versions are manufactured to different standards for different bodies, and the two should never be substituted for one another.